INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

Meeting Minutes

Date: Wednesday, December 14, 2016
Time: 10:00 AM – 12:00 PM

Location: Foege N-130A

Members Present:
1. Thea Brabb, Comparative Medicine *(Animal Containment Expert)*
2. Lesley Colby, Comparative Medicine *(Animal Containment Expert)*
3. Richard Grant, Washington National Primate Research Center
4. Garry Hamilton (*Community Member*)
5. Kevin Hybiske, Allergy and Infectious Diseases
6. David Koelle, Allergy and Infectious Diseases
7. Stephen Libby, Laboratory Medicine (*IBC Chair*)
8. Scott Meschke, Environmental & Occupational Health Sciences
9. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer*)
10. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:05 am. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the November 16, 2016 meeting.
   - A member made a motion to approve the November 16, 2016 minutes. Another member seconded the motion.
   - The committee voted unanimously to approve the November 16, 2016 meeting minutes.

4. **BIOSAFETY OFFICER (BSO) REPORT***:* The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines,* (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.

   a. Biosafety Officer Report
      - Dr. Ratner, Dr. Muller, and Dr. Dills each renewed a BUA involving human source material.
      - Dr. Dacey added a new room to his approval.
      - Dr. Cookson added a non-recombinant *Lactobacillus* species to his approval.
      - Dr. Fuller decided to create a new BUA that is a duplicate of her existing BUA. All of the agents on the newly approved 0538-008 BUA are identical to what was previously approved on BUA #0538-004.
      - Dr. von Moltke received a new BUA approval to use mouse parasite species in mice. The work will be conducted at ABSL-2 in the vivarium until sufficient experimental data is collected to show that the parasites cannot spread from mouse to mouse.
      - The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
      - A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
      - The Committee unanimously voted to approve this month's Biosafety Officer Report.

5. **INDIVIDUAL PROJECT REVIEWS**

   1. Cabernard, Clemens, new, *Cellular and molecular mechanisms of asymmetric cell division*
      - The assigned IBC Primary Reviewer presented the Primary Review.
      - The lab studies how fruit fly cells accurately position molecular machinery required for cell division. Transgenic *Drosophila* flies are used in the project.
      - The lab has successfully passed the lab inspection and all of the required trainings have been completed.
      - The draft BUA letter was shown.
      - The lab is using a confocal laser system. The setup has been reviewed by the Radiation Safety office and the procedures for using the laser and the personal protective equipment is all in place.

- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Cabernard. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Cabernard.

2. Hajjar, Lynn, change, *Linking Innate and Adaptive Immunity*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This is a change request to add wildtype and recombinant *Staphylococcus aureus* strains. The strains are not MRSA (Methicillin-resistant *Staphylococcus aureus*).
- ~~The lab has recently been inspected~~A lab inspection was not required and all of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hajjar. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Hajjar.

3. Klatt, Nichole, new, *SIV/HIV Infection in Adolescents*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This is a new BUA application from an established investigator. The goal of the work is to create a non-human primate model of SIV/SHIV (Simian/Human Immunodeficiency Virus) infection and susceptibility in adolescent females.
- The lab inspection is scheduled for next week. The approval letter will be issued pending the results of the lab inspection. All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Klatt. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Klatt, pending a successful lab inspection.

4. Kobayashi, Akio, renewal, *Genetic Regulation of Nephron Progenitor Cells in the Mammalian Kidney*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This is a renewal. The overall goal of the project is to elucidate the molecular mechanisms regulating kidney development.
- Lentiviral vectors and adenoviral vectors are used on the project.
- A question was raised about lentiviral vectors. If lentiviral vectors are first generation or second generation (or if the generation is not known) the vectors are worked with at BSL-2, or if the vectors contain oncogenic inserts, they are worked with at BSL-2 with BSL-3 practices.
- The lab has successfully passed the lab inspection and all of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kobayashi. A second is not needed since she is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Kobayashi.

5. Liu, Qinghang, renewal, *Liu Lab Research Program*

- The assigned IBC Primary Reviewer presented the Primary Review.

- This is a renewal. The overall goal of the project is to understand molecular mechanisms underlying cardiac cell death and heart failure.
- Adenoviral vectors, lentiviral vectors, and adeno-associated viral vectors (AAV) are used on the project.
- One oncogene used in the project, CASP8, is a tumor suppressor that will be overexpressed. It will be used on a plasmid with no potential for incorporation into the genome and therefore is not viewed as a biosafety concern.
- The draft BUA letter was shown.
- The lab has successfully passed the lab inspection and all of the required trainings have been completed.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Liu. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Liu.

6. Lukehart, Sheila, renewal, *Immunology of Syphilis*

- The assigned IBC Primary Reviewer presented the Primary Review.
- The lab studies *Treponema* species, especially syphilis caused by *Treponema pallidum*. They are particularly interested in identifying potential antigens for vaccines.
- Rabbits are used on the project to propagate *T. pallidum* and related bacteria. These *Treponema* species are not recombinant, and all of the required permits have already been obtained by the investigator.
- The lab has successfully passed the lab inspection and all of the required trainings have been completed.
- There are a few questions on the BUA application that need to be corrected. Also, the BUA application mentions that they will be using dead wild-caught flies. These flies will need to be fully described in the BUA application.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Lukehart. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Lukehart.

7. Moritz, Chet, renewal, *Combined Stem Cell Transplantation and Targeted Microstimulation to Direct the Formation of Functional Connections and Neural Repair in Mice*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This protocol involves mice only. Dr. Moritz also works with rats, and this work used to be included on the same BUA, but he has decided to split the mouse and rat work into two separate BUAs.
- The Moritz lab researches the treatment of damage to the brain, spinal cord, or bladder.
- This project involves using AAV in mice.
- The lab has successfully passed the lab inspection and all of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Moritz. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Moritz.

8. Moritz, Chet, new, *Combined Stem Cell Transplantation and Targeted Microstimulation to Direct the Formation of Functional Connections and Neural Repair in Rats*
    - The assigned IBC Primary Reviewer presented the Primary Review.
    - This protocol involves rats only. Dr. Moritz also works with mice, and this work used to be included on the same BUA, but he has decided to split the mouse and rat work into two separate BUAs.
    - This project involves injecting either a lentiviral vector or AAV into the spinal cords of rats. No known oncogenes are used on the project.
    - The lab has successfully passed the lab inspection and all of the required trainings have been completed.
    - The draft BUA letter was shown.
    - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Moritz. A second is not needed since she is the Primary Reviewer.
    - The Committee voted unanimously to approve the draft BUA for Dr. Moritz.

SUBCOMMITTEE REPORTS:

9. Hawn, Thomas, change, *Innate Immunity and Susceptibility to Infectious Disease*
    - Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
    - This is a change request to a recently approved project. The investigator is requesting to add many mutant strains of Mycobacterium tuberculosis. All of the mutants are on an H37Rv background. None of the mutations are expected to cause any increase in virulence. All of the strains will be handled at BSL-3 containment.
    - All of the required trainings have been completed.
    - An Occupational Health Plan is in place.
    - The ~~draft~~ current BUA letter was shown.
    - A member made a motion to approve the ~~draft BUA letter~~BUA change for Dr. Hawn. Another member seconded the motion.
    - The Committee voted unanimously to approve the draft BUA for Dr. Hawn.

FOR YOUR INFORMATION:

- The Northwest Association for Biomedical Research is hosting an Institutional Biosafety Committee Conference in Seattle on January 25th.

ISSUES FROM THE FLOOR & PUBLIC COMMENTS:

There were no issues from the floor, and no public comments.

MEETING ADJOURNED AT APPROXIMATELY 11:02 a.m.